Notice NOT-AI-19-035 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company's inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to examine the safety and use of two HIV prevention tools -- oral pre-exposure prophylaxis (PrEP) and a vaginal ring -- in adolescent girls and young women in southern Africa. Funded by the National Institutes of Health, the trial is designed to contribute to the delivery of safe, effective and desirable choices of HIV prevention methods for adolescent girls and young women, who are disproportionately affected by the HIV epidemic. (Source: EurekAlert! - Infectious and Emerging Diseases)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2UGrJXc
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company's inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to examine the safety and use of two HIV prevention tools -- oral pre-exposure prophylaxis (PrEP) and a vaginal ring -- in adolescent girls and young women in southern Africa. Funded by the National Institutes of Health, the trial is designed to contribute to the delivery of safe, effective and desirable choices of HIV prevention methods for adolescent girls and young women, who are disproportionately affected by the HIV epidemic. (Source: EurekAlert! - Infectious and Emerging Diseases)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2UGrJXc
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company's inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to examine the safety and use of two HIV prevention tools -- oral pre-exposure prophylaxis (PrEP) and a vaginal ring -- in adolescent girls and young women in southern Africa. Funded by the National Institutes of Health, the trial is designed to contribute to the delivery of safe, effective and desirable choices of HIV prevention methods for adolescent girls and young women, who are disproportionately affected by the HIV epidemic. (Source: EurekAlert! - Infectious and Emerging Diseases)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2UGrJXc
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company's inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to examine the safety and use of two HIV prevention tools -- oral pre-exposure prophylaxis (PrEP) and a vaginal ring -- in adolescent girls and young women in southern Africa. Funded by the National Institutes of Health, the trial is designed to contribute to the delivery of safe, effective and desirable choices of HIV prevention methods for adolescent girls and young women, who are disproportionately affected by the HIV epidemic. (Source: EurekAlert! - Infectious and Emerging Diseases)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2UGrJXc
Over the years, many techniques have been described to correct tear trough deformity (TTD). Fat-repositioning lower blepharoplasty via a transconjunctival approach is increasingly applied due to its satisfactory rejuvenating effect. However, those methods have disadvantages such as a complicated surgical approach, residual scar, and long recovery time.
We modified the surgical technique of fat-repositioning transconjunctival lower blepharoplasty with an effective but easy internal fixation method via a supraperiosteal approach.
From January 2014 to December 2017, 110 patients underwent bilateral modified lower blepharoplasty with fat-repositioning. Preoperatively, the grade of TTD was evaluated according to Barton's grading system. Postoperative results and complications were assessed during the follow-up period.
TTD was ameliorated in 97.73% of the cases; the remaining 2.27% cases with no improvement underwent revision and achieved Grade 0 on Barton's grading system thereafter. All patients were satisfied with the final outcome. Few postoperative complications were observed, none of which led to a permanent condition. Three cases of local depression and one case of local bulge were treated with surgical refinements. One case of postoperative hemorrhage was healed by electrocautery.
Our modified method of transconjunctival lower blepharoplasty with fat repositioning is safe and effective to improve TTD without severe orbital skin laxity.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Over the years, many techniques have been described to correct tear trough deformity (TTD). Fat-repositioning lower blepharoplasty via a transconjunctival approach is increasingly applied due to its satisfactory rejuvenating effect. However, those methods have disadvantages such as a complicated surgical approach, residual scar, and long recovery time.
We modified the surgical technique of fat-repositioning transconjunctival lower blepharoplasty with an effective but easy internal fixation method via a supraperiosteal approach.
From January 2014 to December 2017, 110 patients underwent bilateral modified lower blepharoplasty with fat-repositioning. Preoperatively, the grade of TTD was evaluated according to Barton's grading system. Postoperative results and complications were assessed during the follow-up period.
TTD was ameliorated in 97.73% of the cases; the remaining 2.27% cases with no improvement underwent revision and achieved Grade 0 on Barton's grading system thereafter. All patients were satisfied with the final outcome. Few postoperative complications were observed, none of which led to a permanent condition. Three cases of local depression and one case of local bulge were treated with surgical refinements. One case of postoperative hemorrhage was healed by electrocautery.
Our modified method of transconjunctival lower blepharoplasty with fat repositioning is safe and effective to improve TTD without severe orbital skin laxity.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Over the years, many techniques have been described to correct tear trough deformity (TTD). Fat-repositioning lower blepharoplasty via a transconjunctival approach is increasingly applied due to its satisfactory rejuvenating effect. However, those methods have disadvantages such as a complicated surgical approach, residual scar, and long recovery time.
We modified the surgical technique of fat-repositioning transconjunctival lower blepharoplasty with an effective but easy internal fixation method via a supraperiosteal approach.
From January 2014 to December 2017, 110 patients underwent bilateral modified lower blepharoplasty with fat-repositioning. Preoperatively, the grade of TTD was evaluated according to Barton's grading system. Postoperative results and complications were assessed during the follow-up period.
TTD was ameliorated in 97.73% of the cases; the remaining 2.27% cases with no improvement underwent revision and achieved Grade 0 on Barton's grading system thereafter. All patients were satisfied with the final outcome. Few postoperative complications were observed, none of which led to a permanent condition. Three cases of local depression and one case of local bulge were treated with surgical refinements. One case of postoperative hemorrhage was healed by electrocautery.
Our modified method of transconjunctival lower blepharoplasty with fat repositioning is safe and effective to improve TTD without severe orbital skin laxity.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
AbstractTo study the role of Otoacoustic emission test in neonatal screening at tertiary center. The study was conducted in the ENT department of LN medical college and JK hospital Bhopal (M.P) as a territory center between 2015 and 2017 were 1250 newborns were screened with Otoacoustic emission test with portableInteracoustics OAE DK-5610 assens an routine screening investigation. In our study a multistep screening with OAE was done, 1250 newborns (659 boys and 591 girls) were assessed. In our study we have found that OAE has 66.7% sensitivity and 98.8% specificity in diagnosis of neonatal hearing impairment. Its positive and negative predictive value was 33.3% and 99.7% respectively. It is essential to examine the generalized development of newborns by identifying hearing loss at birth a...
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2BpjxTX
AbstractHypothyroidism is a common condition in which thyroid gland doesn 't produce sufficient thyroid hormone. Normal range of TSH is 0.4 to 4 mIU/L. Patients with TSH between 5 and 10 mIU/L, with normal T4 are diagnosed to have subclinical hypothyroidism. Decision to treat, particularly the subclinical hypothyroidism is tailored to individual patients. In our study, isovolumetric relaxation time (IVRT) was used to detect the diastolic function of cardia in hypothyroid patient, with the help of 2D echocardiogram. Normal duration of IVRT is 54 to 65 μs and in hypothyroidism it is expected to increase. To assess, whether IVRT is an effective tool in the management of subclinical hypothyroidism. 50 patients attending otorhinolaryngology OPD with TSH level of 5 to 10 mIU/L were selected...
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2TDg8bc
